by 340B Report
Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report’s newsroom for a candid, insider’s perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
Language
🇺🇲
Publishing Since
9/3/2024
Email Addresses
1 available
Phone Numbers
0 available
April 28, 2025
<p dir="ltr">In this episode, 340B Report Publisher & CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski to break down the latest developments in the 340B space. The team discusses Senate HELP Committee Chair Bill Cassidy’s (R-La.) high-profile report on the 340B program, an executive order sparking concerns among providers, reactions to potential pharmaceutical tariffs and important state 340B bills in Indiana and Tennessee.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>Senate Report Calls for Congressional 340B Reform</strong></p> <p dir="ltr">Sen. Cassidy unveiled the long-awaited findings of his two-year investigation into the 340B program with a 200-page report that criticized multiple 340B providers and called for significant congressional 340B reform that echoes many drug industry policy asks. Shannon and Ted discuss the implications of the report and stakeholder reactions to it, as well as the latest on a separate bipartisan Senate 340B legislative effort that’s expected to be more provider friendly. </p> <p dir="ltr"><strong>Executive Order and Tariffs Spark Concerns</strong></p> <p dir="ltr">Will Newton breaks down President Donald Trump’s (R) recent executive order that attempts to revive a controversial rule requiring health centers to pass all 340B savings on insulin and EpiPens directly to certain low-income patients. The order also calls for a survey on hospital acquisition costs—the likely precursor to an attempt to reduce Medicare Part B payments to 340B hospitals. Providers have raised alarm bells over both proposals. Bella discusses the administration’s proposed tariffs on pharmaceuticals and why both drugmakers and provider advocates are warning that they could be problematic for the pharmaceutical supply and patients.</p> <p dir="ltr"><strong>State 340B Bills in Indiana and Tennessee</strong></p> <p dir="ltr">Will breaks down a 340B hospital reporting bill in Indiana and a contract pharmacy bill in Tennessee that are both likely to soon become law. Tennessee’s unique bill grandfathers in existing drugmaker 340B restrictions but requires the “winners-only” contract pharmacy model that’s popular among providers. </p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. This week’s episode is sponsored by Pillr Health, a company known for its 340B solutions that emphasize transparency, integrity, and ease of use for covered entities. Visit <a href="https://www.pillrhealth.com/">PillrHealth.com</a> to learn more.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">We’re offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.</p> <p> </p>
April 14, 2025
<p dir="ltr">In this episode, 340B Report Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Bella Czajkowski break down the latest in 340B news, including the latest states to enact contract pharmacy access laws, updates in key lawsuits and new U.S. Department of Health and Human Services (HHS) restructuring efforts.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>New State Contract Pharmacy Access Laws</strong><br /> Will highlights new contract pharmacy access laws enacted in Nebraska and Utah, including when they take effect and how their respective state governors approached the legislation. He also briefly discusses New Mexico’s newly enacted contract pharmacy access law, which does not take effect until 2026 and is the only enacted state contract pharmacy protection statute that only applies to health centers.</p> <p dir="ltr"><strong>Key Updates in Drug Industry Lawsuits and State Enforcement Action</strong><br /> Will also breaks down a Minnesota federal district judge’s order to dismiss two drug industry lawsuits challenging that state’s contract pharmacy access law. The judge ruled that the drugmakers had no legal standing to sue the state over its contract pharmacy law since Minnesota’s law—unlike most other existing state contract pharmacy protection statutes—has no enforcement mechanism. Meanwhile, in Arkansas, a state official recently ordered AstraZeneca to restore access to 340B drugs at all contract pharmacy locations. AstraZeneca had been the only major manufacturer not to comply with Arkansas’ first-in-the-nation contract pharmacy access law after a federal appeals court panel unanimously upheld the statute in March 2024.</p> <p dir="ltr"><strong>A New CMS Leader and HHS Restructuring</strong></p> <p dir="ltr">Shannon and Bella provide an update on 340B-related activity at the federal level. Bella discusses the U.S. Senate’s recent confirmation of Mehmet Oz as the new administrator of the Centers for Medicare and Medicaid Services (CMS). Shannon highlights the recent restructuring at HHS and rumored efforts to move the 340B program into CMS. </p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. <a href= "https://verity-solutions.com/">Verity Solutions</a> sponsored this week’s episode. Verity’s innovative, award-winning 340B program management solutions are designed to optimize your 340B pharmacy spend and maximize your pharmacy supply chain savings. We are very grateful to Verity for its sponsorship.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">We’re offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href="https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.</p>
March 31, 2025
<p dir="ltr">In this episode, the Inside 340B Report team dives into a flurry of activity at the state and federal levels. Publisher and CEO Ted Slafsky and Associate Editor/Senior Writers Shannon Young and Will Newton break down the unprecedented wave of state-level 340B contract pharmacy access and provider reporting bills, explore key federal movements, including the latest on the bipartisan U.S. Senate working group behind the SUSTAIN 340B Act, and provide an update on 340B rebate litigation.</p> <p dir="ltr"><strong>Key Topics Covered:</strong></p> <p dir="ltr"><strong>State Legislative Activity Heats Up</strong><br /> The team discusses the recent surge in legislative action on state 340B bills as more than 25 states have introduced contract pharmacy access bills in 2025. South Dakota and Utah recently enacted contract pharmacy laws in 2025, joining eight other states that passed similar bills in previous years, while bills in New Mexico and North Dakota are awaiting action from their state governors. Will also highlights several state bills that would place a range of reporting requirements—and in some cases significant restrictions—on 340B providers.</p> <p dir="ltr"><strong>Federal Legislative Developments and Bipartisan Efforts</strong><br /> Shannon provides updates on the latest developments on the 340B front in Washington, D.C., including the new members of the bipartisan group of six senators working on 340B overhaul legislation known as the SUSTAIN 340B Act. She and Ted also highlight other federal bills that could resurface this session, including the provider-supported 340B PATIENTS Act and drug industry-backed 340B ACCESS Act. The team also provides an update on Mehmet Oz’s nomination to lead the Centers for Medicare & Medicaid Services (CMS), focusing on a new Washington Post story that highlighted 340B Report’s previous reporting on his undisclosed ties to ZorroRx, a health benefits company that partners with 340B hospitals. Despite facing new ethics concerns, Oz has not drawn much scrutiny from lawmakers during the confirmation process over his 340B ties or stance on the program—a shift from previous nominees.</p> <p dir="ltr"><strong>Rebate Litigation Developments</strong><br /> Will explains recent developments in ongoing lawsuits that pharmaceutical giants, like Johnson & Johnson and Eli Lilly, have filed against the federal Health Resources and Services Administration (HRSA) in their attempts to unilaterally impose 340B rebate models. Notably, in a series of recent court filings, President Donald Trump’s (R) administration has chosen to continue to defend HRSA’s long-standing position that drugmakers cannot implement 340B rebate models without explicit agency approval, offering some relief to the 340B provider community.</p> <p dir="ltr"><strong>Subscribe & Stay Updated</strong></p> <p dir="ltr"><strong>How to Follow Us and Learn More About This Episode’s Sponsor</strong></p> <p dir="ltr">Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions.</p> <p dir="ltr">Each episode is brought to you by one of our great Ultra Diamond sponsors. This episode is sponsored by <a href= "http://compassrx.com">CompassRx</a>, the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize your 340B savings and operational efficiency.</p> <p dir="ltr"><strong>Subscribe to 340B Report with a Special Discount</strong></p> <p dir="ltr">Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may <a href= "https://340breport.com/subscribe/">subscribe now</a> using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day <a href= "https://subscribers.340breport.com/checkout?plan=59319">free trial</a>.<strong id= "docs-internal-guid-ff982063-7fff-c33d-0f37-44143b25da57"></strong></p>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.
